pulmonary%20arterial%20hypertension
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.

Pulmonary%20arterial%20hypertension Signs and Symptoms

Introduction

  • A syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and remodeling, and ultimately leading to right heart failure

Definition

  • Pulmonary arterial hypertension (PAH) is part of the spectrum of pulmonary hypertension (PH), which is a hemodynamic and pathophysiological condition
    • Precapillary PH defined as an increase in mean pulmonary arterial pressure (mPAP) >20 mmHg, pulmonary arterial wedge pressure (PAWP) of ≤15 mmHg, and pulmonary vascular resistance (PVR) of ≥3 Wood Units (WU), with all measurements taken at rest
    • Isolated post-capillary PH is defined as mPAP >20 mmHg, PAWP >15 mmHg and PVR <3 WU
    • Combined pre- and post-capillary PH is defined as mPAP >20 mmHg, PAWP >15 mmHg and PVR ≥3 WU

Signs and Symptoms

Typical Symptoms

  • Progressive dyspnea on exertion, palpitations
  • Fatigue, weakness, angina, syncope, abdominal distention
  • Less commonly: Hemoptysis, Raynaud’s phenomenon

Risk Factors and Associated Conditions for Pulmonary Arterial Hypertension

Drugs and Toxins
  • Definite association: Aminorex, Fenfluramine, Dexfenfluramine, Benfluorex, methamphetamines, Dasatinib, selective serotonin reuptake inhibitors, toxic grapeseed oil
  • Possible association: Cocaine, Phenylpropanolamine, L-tryptophan, chemotherapeutic agents (Mitomycin C, Cyclophosphamide), Interferon α and β, St. John’s Wort, amphetamines, Bosutinib, direct-acting antiviral agents against hepatitis C virus infection (eg Sofosbuvir), Leflunomide and Indirubin
  • Unlikely associated with PAH: Oral contraceptives, Estrogen therapy, cigarette smoking
Demographic Factors
  • Definite association: Gender
  • Possible association: Pregnancy, systemic hypertension
  • Unlikely associated with pulmonary arterial hypertension: Obesity
Medical Conditions
  • Definite association: HIV infection, severe symptomatic mitral or aortic valve disease
  • Likely association: Portal hypertension or liver disease, collagen vascular diseases, congenital systemic-to-pulmonary cardiac shunts
  • Possible association: Thyroid disorders, hematological conditions (eg asplenia 2° to surgical splenectomy, sickle cell disease, β-thalassemia, chronic myeloproliferative disorders), rare genetic or metabolic diseases (eg Type 1a glycogen storage disease, Gaucher’s disease, hereditary hemorrhagic telangiectasia)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 03 Aug 2020
Adding the anti-GM-CSF* receptor-α monoclonal antibody mavrilimumab to standard care (SC) improved clinical outcomes in patients with severe coronavirus disease 2019 (COVID-19) pneumonia and systemic hyperinflammation who were not under mechanical ventilation (MV), an Italian study has shown.
Pearl Toh, 08 Dec 2020
Intravenous (IV) antibiotics are no better than oral antibiotics when it comes to eradicating Pseudomonas (P.) aeruginosa in children and adults with cystic fibrosis, yet are more costly than the latter, reveals the TORPEDO-CF study.
Rachel Soon, 05 Dec 2020

The Malaysian National Immunisation Programme (NIP) will now include a hexavalent combination DTaP-IPV-HiB-HepB vaccine and a pneumococcal vaccine.

Elvira Manzano, 12 Dec 2020
Having asthma or allergy does not make COVID-19 severe, a new study presented at ACAAI 2020 has shown.